Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15180378 | 1.00 | TAAR1 (0.41) | TAAR1HTR2ANQO2MTNR1AMTNR1B | |
| SCHEMBL15158458 | 0.93 | NQO2 (0.41) | TAAR1HTR2ANQO2MTNR1AMTNR1B | |
| SCHEMBL4246217 | 0.93 | NQO2 (0.41) | TAAR1HTR2ANQO2MTNR1AMTNR1B | |
| SCHEMBL383341 | 0.88 | CYP3A4 (0.43) | HTR2ANQO2MTNR1AMTNR1BCHRM2 | |
| SCHEMBL7436614 | 0.88 | CYP3A4 (0.43) | HTR2ANQO2MTNR1AMTNR1BCHRM2 | |
| SCHEMBL31549 | 0.88 | CYP3A4 (0.43) | HTR2ANQO2MTNR1AMTNR1BCHRM2 | |
| SCHEMBL7911834 | 0.88 | CYP3A4 (0.43) | HTR2ANQO2MTNR1AMTNR1BCHRM2 | |
| SCHEMBL31936524 | 0.88 | CYP3A4 (0.43) | HTR2ANQO2MTNR1AMTNR1BCHRM2 | |
| SCHEMBL4746611 | 0.87 | TAAR1 (0.42) | TAAR1NQO2MTNR1AMTNR1BCHRM2 | |
| SCHEMBL4746590 | 0.87 | TAAR1 (0.42) | TAAR1NQO2MTNR1AMTNR1BCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076325-B2 | 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-12-13 | — | — | US | disclosed |
| EP-2036892-B1 | 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2010-03-10 | — | — | EP | disclosed |
| WO-2009066041-A2 | DERIVATIVES OF 1,2,4,5-TETRAHYDRO-3H-BENZAZEPINES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2009-05-28 | — | — | WO | disclosed |
| EP-2036892-A1 | 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-03-18 | — | — | EP | disclosed |
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | OXER1, NR1H3, OXSR1 | TAAR1 279/4885HTR2A 223/4885NQO2 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.